U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation - Haratani, Koji; Yonesaka, Kimio; Takamura, Shiki; Maenishi, Osamu; Kato, Ryoji; Takegawa, Naoki; Kawakami, Hisato; Tanaka, Kaoru; Hayashi, Hidetoshi; Takeda, Masayuki; Maeda, Naoyuki; Kagari, Takashi; et al. (The Journal of clinical investigation, 2020)
Keywords: Analysis; Antibodies; Apoptosis; Atezolizumab; Avelumab; Biochemistry; Biological products; Cancer; Cell death; Chemotherapy; Chromosomal proteins; Durvalumab; Epidermal growth factors; Health aspects; Immunotherapy; Nivolumab; Pembrolizumab; Tumors; Japan; Cancer immunotherapy; Oncology